Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.

about

Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.

Item

http://www.wikidata.org/entity/Q42279573

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@en

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@nl

type

Item

label

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@en

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@nl

prefLabel

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@en

Uncommon response of cisplatin ...... d medullary thyroid carcinoma.

@nl

P1476

Uncommon response of cisplatin ...... ed medullary thyroid carcinoma

@en

P2093

Chuleeporn Jiarpinitnun

http://www.w3.org/2001/XMLSchema#string

Jariya Waisayarat

http://www.w3.org/2001/XMLSchema#string

Nathamon Panomuppakarn

http://www.w3.org/2001/XMLSchema#string

Patamintita Witoonpanich

http://www.w3.org/2001/XMLSchema#string

Touch Ativitavas

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of metastatic medullary thyroid cancer

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

Cabozantinib in progressive medullary thyroid cancer.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

The evolving landscape of neuroendocrine tumors.

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Biologic and Clinical Perspectives on Thyroid Cancer.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen.

P304

1628-1633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1002/CCR3.1123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nuttapong Ngamphaiboon

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29026560

http://www.w3.org/2001/XMLSchema#string

P932

5628208

http://www.w3.org/2001/XMLSchema#string